• Nuvalent named Georg Pirmin Meyer as chief international officer to lead its international expansion strategy and build presence in key markets outside the U.S.
• Meyer most recently served as senior vice president and general manager, international at Blueprint Medicines, leading European launches of Ayvakit across three indications.
• Earlier roles included general manager, Germany at Vertex Pharmaceuticals, with prior global commercial positions at Amgen and Sanofi.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvalent Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605270630PR_NEWS_USPR_____NE68545) on May 27, 2026, and is solely responsible for the information contained therein.